Medical Doctor Program year 2023 Reported 2022–2023 Source: CMS Open Payments, 2026 publication

Weera Sukhumthammarat

Geriatric Medicine Richmond, VA Medical Doctor

NPI 1619407806 CMS profile 11323193

2116 W Laburnum Ave, Richmond, VA 23227

Open in the dashboard

General payments

$69

3 records reported · program years 2022–2023

Research payments

$0

Paid to them · None reported · program years 2022–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Weera Sukhumthammarat of Richmond, VA is reported in the CMS Open Payments database as having received $69 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $41 2
2022 General $28 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Weera Sukhumthammarat
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Weera Sukhumthammarat were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Weera Sukhumthammarat Geriatric Medicine median Middle half National median
2019 $0 $122 $40–$435 $163
2020 $0 $98 $25–$349 $114
2021 $0 $125 $34–$441 $132
2022 $28 $124 $36–$408 $149
2023 $41 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2022–2023
  1. Biohaven Pharmaceutical Holding Company Ltd. $28 1 payment
  2. Exact Sciences Corporation $23 1 payment
  3. Pfizer Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2023
  1. Food and Beverage $69 3 payments
Products named General payments · program years 2022–2023
  1. NURTEC ODT Primary Care $28 1 payment
  2. Cologuard Collection Kit $23 1 payment
  3. NURTEC ODT Pain $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,333

Median for Geriatric Medicine: 2,306

Drug cost

$197,553

Median for Geriatric Medicine: $150,713

Branded share of claims

17.2%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $53,802
Jardiance Empagliflozin Brand 20 $29,343
Mounjaro Tirzepatide Brand 21 $26,544
Trulicity Dulaglutide Brand 21 $26,087
Ozempic Semaglutide Brand 22 $24,809
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 14 $4,878
Donepezil Hcl Generic 60 $2,337
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $2,226
Albuterol Sulfate Hfa Albuterol Sulfate Brand 44 $1,712
Rosuvastatin Calcium Generic 101 $1,624

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$61,561

Of which drugs: $5,165

Medicare patients

345

Average age 77

Services billed

774

210 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Ischemic heart disease 36%
Depression 36%
Diabetes 35%
Osteoporosis 34%
Chronic kidney disease 32%
Heart failure 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,655

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record